ASCO 2025 – J&J takes another prostate cancer shot
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
Astra stumbles again with Truqap
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
